With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs delivers ...
Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results